ClinicalTrials.gg
Active, not recruitingNCT05856799DANVERSUpdated Apr 29, 2026

Danish Randomized Trial on Leadless vs Transvenous Pacing

An interventional study of Leadless Micra AV Transcatheter Pacing System and Transvenous Azure XT DR dual chamber pacemaker in AV Block, sponsored by University of Aarhus. Active, not recruiting at 2 sites in Denmark. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Atrioventricular Block with a site in Denmark — 1 open to participants now, 2 under way, none of them phase 3. Atrioventricular Block · Denmark.

Started
2023
the only one that year
No phase
4 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
University of Aarhus

Among the 11 studies in Atrioventricular Block with a site in Denmark, this one is the only one that started in 2023, is one of 4 with no phase, and was the 11th registered.

Atrioventricular Block

118 studies on the registry are indexed under Atrioventricular Block; 44 are open to participants now.

Browse Atrioventricular Block studies →

Open to participants now

1 of the 11 studies in Atrioventricular Block with a site in Denmark is open now. Recruiting first, the newest first:

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 29 Atrioventricular Block studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Atrioventricular Block with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the quality of life, patient acceptance and exercise capacity with leadless compared to transvenous pacing in elderly patients with new-onset high-grade atrioventricular block. Consecutive patients with high-grade atrioventricular black and preserved sinus node function with indication for permanent pacemaker implantation according to the latest european guidelines, are included in a prospective, partly patient and accessor blinded and partly open label, 1:1 randomized combined parallel and cross-over trial to implantation with 1) a Micra AV Transcathter Pacing System or 2) an Azure XT DR dual chamber pacemaker.

03

Conditions studied

  • AV Block

Keywords

  • Leadless Pacing
  • Cardiac Pacemaker
  • Cardiac Arrythmia
  • Heart Disease
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First time pacemaker implantation on class I or II ESC recommendations for AVB with an expected amount of right ventricular pacing >80% of the time,
  • Age 75 years or older
  • Intact sinus node function
  • Expected survival more than 12 months based on clinical evaluation
  • Able to provide

Exclusion criteria

Exclusion criteria:

  • Persistent or previous cardiac implantable electronic device i.e., pacemaker, ICD, or CRT.
  • Persistent, or chronic atrial fibrillation
  • Reversible AVB
  • Transient AVB due to ongoing ischemia
  • Heart failure class III-IV
  • Heart failure with branch block and indication for CRT implantation, irrespective of NYHA class
  • Indication for primary or secondary prophylactic ICD implantation
  • Acute myocardial infarction (AMI) within 3 months
  • Severe chronic pulmonary disease with pulmonal hypertension limiting exercise capacity
  • Expected survival \< 12 months based on clinical evaluation
  • Performing high intensity sport
  • Participation in another trial with experimental treatment
  • against device implantation (e.g., concurrent infection)
  • Failure to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Leadless Pacemaker

    Implantation with a leadless pacemaker

    Device: Leadless Micra AV Transcatheter Pacing System

  • Active comparator
    Transvenous pacemaker

    Implantation with a transvenous pacemaker

    Device: Transvenous Azure XT DR dual chamber pacemaker

Interventions

  • DeviceLeadless Micra AV Transcatheter Pacing System

    Patients are implanted with a leadless Micra AV TPS

  • DeviceTransvenous Azure XT DR dual chamber pacemaker

    Patients are implanted with a transvenous Azure XT DR pacemaker

06

What researchers measure

Primary outcomes

  1. Quality of Life by SF36

    Self-reported health-related quality of life as measured by Short-Form 36 quality of life questionnaire. The scale ranges from 0 to 100. 0 denotes minimal quality of life and 100 denotes maximum quality of life.

    Time frame: 7 months

Secondary outcomes

  1. Patient Acceptance by FPAS

    Self-reported patient acceptance as measured by Florida Patient Acceptance Scale. The scale ranges from 0-100. 0 denotes minimal device acceptance and 100 denotes maximal device acceptance.

    Time frame: 7 months

  2. Exercise capacity by 6MWT

    Exercise capacity as measured by 6-minute walk test

    Time frame: 7 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — In accordance with Danish and European data protection law

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 44 interventional studies with no phase under Atrioventricular Block, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
May 12, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05856799
Responsible party
Sponsor
First posted
May 12, 2023
Start date
Sep 1, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Mads B. Kronborg, DMSc
principal investigator · Department of Cardiology Aarhus University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion